SNDX - Syndax Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Waltham,
United States
Type: Equity
SNDX price evolution
SNDX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $105.61 | $114.83 | $295.61 | |
| Short term investments | $326.87 | $328.55 | $282.19 | |
| Net receivables | $4.69 | $9.58 | $6.07 | $1.23 |
| Inventory | ||||
| Total current assets | $414.81 | $446.06 | $453.9 | $580.88 |
| Long term investments | $29.52 | $87.42 | $29.83 | |
| Property, plant & equipment | $0.76 | $1 | $1.25 | $1.5 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $30.89 | $89.13 | $32 | |
| Total investments | $356.39 | $415.96 | $312.02 | |
| Total assets | $425.81 | $476.95 | $543.03 | $612.88 |
| Current liabilities | ||||
| Accounts payable | $4.9 | $14.67 | $16.36 | $17.19 |
| Deferred revenue | ||||
| Short long term debt | $0.99 | $1.05 | $1.05 | |
| Total current liabilities | $59.38 | $42.47 | $50.8 | $58.1 |
| Long term debt | $0 | $0.14 | $0.33 | $0.59 |
| Total noncurrent liabilities | $0.14 | $0.33 | $0.59 | |
| Total debt | $1.13 | $1.39 | $1.64 | |
| Total liabilities | $59.38 | $42.61 | $51.14 | $58.68 |
| Shareholders' equity | ||||
| Retained earnings | -$1126.99 | -$1042.86 | -$974.8 | -$902.4 |
| Other shareholder equity | $0.37 | -$0.82 | -$0.76 | $0.22 |
| Total shareholder equity | $434.34 | $491.89 | $554.2 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $295.61 | $74.47 | $222.08 | $115.36 |
| Short term investments | $282.19 | $410.04 | $217.97 | $177.82 |
| Net receivables | $1.23 | $4.06 | $0.43 | $0.2 |
| Inventory | ||||
| Total current assets | $580.88 | $489.79 | $448.4 | $298.86 |
| Long term investments | $29.83 | $5.47 | ||
| Property, plant & equipment | $1.5 | $1.06 | $1.26 | $0.48 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $32 | $7.45 | $1.26 | $1.75 |
| Total investments | $312.02 | $415.51 | $217.97 | $177.82 |
| Total assets | $612.88 | $497.24 | $449.66 | $300.61 |
| Current liabilities | ||||
| Accounts payable | $17.19 | $4.35 | $5.67 | $3.51 |
| Deferred revenue | $13.13 | |||
| Short long term debt | $1.05 | $0.44 | $0.36 | $2.6 |
| Total current liabilities | $58.1 | $29.07 | $20.68 | $18.87 |
| Long term debt | $0.59 | $0.01 | $20.61 | $17.93 |
| Total noncurrent liabilities | $0.59 | $0.72 | $20.61 | $29.55 |
| Total debt | $1.64 | $1.16 | $20.97 | $20.54 |
| Total liabilities | $58.68 | $29.79 | $41.29 | $48.42 |
| Shareholders' equity | ||||
| Retained earnings | -$902.4 | -$693.04 | -$543.7 | -$568.63 |
| Other shareholder equity | $0.22 | -$0.81 | $0.04 | -$0 |
| Total shareholder equity | $554.2 | $467.45 | $408.37 | $252.19 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $12.5 | $3.5 | ||
| Cost of revenue | ||||
| Gross Profit | $3.5 | |||
| Operating activities | ||||
| Research & development | $48.66 | $56.49 | $55.13 | |
| Selling, general & administrative | $29.06 | $23.02 | $22.78 | |
| Total operating expenses | $102.08 | $77.72 | $79.51 | $77.91 |
| Operating income | -$74.22 | -$79.51 | -$77.91 | |
| Income from continuing operations | ||||
| EBIT | -$68.02 | -$72.34 | -$72.41 | |
| Income tax expense | ||||
| Interest expense | $5.42 | $0.04 | $0.06 | $0.06 |
| Net income | ||||
| Net income | -$84.13 | -$68.06 | -$72.4 | -$72.47 |
| Income (for common shares) | -$68.06 | -$72.4 | -$72.47 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $139.71 | $1.52 | ||
| Cost of revenue | ||||
| Gross Profit | $139.71 | $1.52 | ||
| Operating activities | ||||
| Research & development | $163.03 | $118.5 | $88.25 | $50.44 |
| Selling, general & administrative | $66.92 | $33.26 | $25.24 | $22.5 |
| Total operating expenses | $229.95 | $151.76 | $113.49 | $72.94 |
| Operating income | -$229.95 | -$151.76 | $26.22 | -$71.42 |
| Income from continuing operations | ||||
| EBIT | -$209.15 | -$146.2 | $26.82 | -$74.71 |
| Income tax expense | ||||
| Interest expense | $0.21 | $3.14 | $1.9 | $2.36 |
| Net income | ||||
| Net income | -$209.36 | -$149.34 | $24.93 | -$77.06 |
| Income (for common shares) | -$209.36 | -$149.34 | $24.93 | -$77.06 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$68.06 | -$72.4 | -$72.47 | |
| Operating activities | ||||
| Depreciation | $0.24 | $0.25 | $0.25 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.9 | $8.9 | $8.33 | |
| Total cash flows from operations | -$71.64 | -$83.55 | -$41.35 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $61.75 | -$99.4 | -$16.29 | |
| Total cash flows from investing | $49.2 | $61.75 | -$99.4 | -$16.29 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.68 | $2.17 | $258.48 | |
| Net borrowings | ||||
| Total cash flows from financing | $5.94 | $0.68 | $2.17 | $258.48 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$162.37 | -$9.22 | -$180.78 | $200.84 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$209.36 | -$149.34 | $24.93 | -$77.06 |
| Operating activities | ||||
| Depreciation | $0.75 | $0.45 | $0.46 | $0.52 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $30.95 | $16.02 | $13.32 | $9.06 |
| Total cash flows from operations | -$160.6 | -$133.68 | $29.13 | -$71.26 |
| Investing activities | ||||
| Capital expenditures | $0.23 | -$0.13 | ||
| Investments | $117.61 | -$186.41 | -$40.74 | -$142.53 |
| Total cash flows from investing | $117.61 | -$186.19 | -$40.87 | -$142.53 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $264.13 | $193.25 | $117.89 | $284.69 |
| Net borrowings | -$21 | $0.58 | $19.73 | |
| Total cash flows from financing | $264.13 | $172.25 | $118.46 | $304.42 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $221.14 | -$147.61 | $106.72 | $90.63 |
News
Fundamentals
| Market cap | $962.68M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 85.57M |
| Revenue | $16.00M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$297.06M |
| Revenue Q/Q | InfinityT% |
| Revenue Y/Y | N/A |
| P/E ratio | -3.24 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 60.17 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.47 |
|---|---|
| ROA | -57.72% |
| ROE | N/A |
| Debt/Equity | 0.11 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.99 |
| Quick ratio | N/A |